Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • PRESCRIPTION DRUGS—D.D.C.: IRA’s Drug Price Negotiation Program not unconstitutional, federal trial court holds
    • BILLING AND CODING—SETTLEMENT AGREEMENTS: In-home health provider will pay $2.4 million to settle Medicare Advantage false coding claim
    • CONDITIONS OF PARTICIPATION—DAB DECISIONS: Patient abuse and neglect conviction basis for 5-year exclusion, despite being ‘excessively harsh’ according to ALJ
    • CONTROLLED SUBSTANCES—FINAL RULES: DEA targets emerging kratom-derived opioids with Schedule I action
    • CONTROLLED SUBSTANCES—NOTICES: FDA seeks input on global drug controls
    • DRUGS AND BIOLOGICS—NOTICES: FDA clears path for generic Cabazitaxel
    • FALSE CLAIMS ACT—D. Mass.: Court grants in part motions to quash subpoenas of non-parties in qui tam action
    • GENERIC DRUGS—D.C. Cir.: Norwich wins partial appeal over rifaximin exclusivity dispute; court orders FDA reconsideration
    • HATCH WAXMAN ACT—D. Del.: Court rejects Vertex bid to expand ivacaftor patent scope
    • MEDICAID—GAO REPORTS: Millions of working adults, many employed by the nation’s largest companies, remain enrolled in Medicaid and SNAP
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, CONTROLLED SUBSTANCES—NOTICES: FDA seeks input on global drug controls, (Aug 28, 2026)

    By WK Editorial Staff

    FDA requested public input to support international reviews of eight substances that may face new global drug-control restrictions.

    The FDA is seeking public comment on eight drug substances that are being reviewed by the World Health Organization ...

    By WK Editorial Staff

    FDA requested public input to support international reviews of eight substances that may face new global drug-control restrictions.

    The FDA is seeking public comment on eight drug substances that are being reviewed by the World Health Organization’s Expert Committee on Drug Dependence (ECDD) for possible international scheduling under global drug control treaties. The substances include six drugs undergoing critical review, such as the synthetic opioids cychlorphine, etomethazene, and spirochlorphine, and the designer benzodiazepines clobromazolam, desalkylgidazepam, and ethylbromazolam, as well as two drugs undergoing pre-review, etomidate and medetomidine. FDA said the substances have been associated with concerns including abuse potential, illicit trafficking, overdose risks, and public health harms, while some also have recognized medical or veterinary uses. Comments submitted to FDA will help inform HHS’s scientific and medical evaluation of the substances before the agency provides input to the ECDD on whether international controls should be recommended (Notice, 91 Fed. Reg. 55098 (Aug. 26, 2026)).

    Dates. Either electronic or written comments must be submitted by September 3, 2026.

    FederalRegisterIssuances: FinalRules ControlledNews DrugBiologicNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use